RNF38 promotes gilteritinib resistance in acute myeloid leukemia via inducing autophagy by regulating ubiquitination of LMX1A.

IF 5.3 2区 医学 Q2 CELL BIOLOGY
Yiyun Pan, Wen Zeng, Ting Liang, Xiaoming Nie, Kang Liu, Hailong Chen, Nengping Luo, Xiaodan Zhu, Keqiang Tian, Yijian Chen
{"title":"RNF38 promotes gilteritinib resistance in acute myeloid leukemia via inducing autophagy by regulating ubiquitination of LMX1A.","authors":"Yiyun Pan, Wen Zeng, Ting Liang, Xiaoming Nie, Kang Liu, Hailong Chen, Nengping Luo, Xiaodan Zhu, Keqiang Tian, Yijian Chen","doi":"10.1007/s10565-024-09936-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Gilteritinib is a commonly used targeted drug for acute myeloid leukemia (AML), but the emergence of gilteritinib resistance greatly reduces the therapeutic effect. RING finger protein 38 (RNF38), a protein with RING Finger domain and E3 ubiquitin ligase activity, has been implicated in tumorigenesis and drug resistance. However, the role and mechanism of RNF38 in the gilteritinib resistance of AML remains unclear.</p><p><strong>Methods: </strong>Normal AML cells were treated with gilteritinib to construct gilteritinib-resistant cells (MV4-11/Gilteritinib and MOLM-13/Gilteritinib). CCK8 assay, TUNEL staining and EdU assay were used to assess gilteritinib resistance, cell apoptosis and proliferation. The protein levels of autophagy-related markers, RNF38 and LIM homeobox transcription factor 1 alpha (LMX1A) were determined by western blot. Also, RNF38 and LMX1A mRNA levels were tested using qRT-PCR. Autophagic flux was assessed using mRFP-GFP-LC3 labeling, and autophagosome numbers was counted under transmission electron microscopy. Co-IP assay was employed to analyze interaction between RNF38 and LMX1A. The effects of LMX1A and RNF38 on AML tumorigenesis were analyzed by in vivo experiments.</p><p><strong>Results: </strong>In gilteritinib-resistant AML cells, autophagy-related markers, mRFP-GFP-LC3 signals and autophagosome numbers were significantly enhanced. Autophagy inhibitor 3-MA could suppress gilteritinib resistance in AML cells. RNF38 knockdown inhibited gilteritinib resistance and autophagy in AML cells. Mechanistically, RNF38 reduced LMX1A expression by inducing its ubiquitination. RNF38 overexpression reversed the inhibitory effect of LMX1A on gilteritinib resistance and autophagy in AML cells, as well as AML tumor growth in vivo, while these effects could be abolished by proteasome inhibitor MG132.</p><p><strong>Conclusions: </strong>RNF38 induced autophagy to promote gilteritinib resistance in AML by increasing the ubiquitination of LMX1A.</p>","PeriodicalId":9672,"journal":{"name":"Cell Biology and Toxicology","volume":"40 1","pages":"105"},"PeriodicalIF":5.3000,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11602842/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell Biology and Toxicology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10565-024-09936-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Gilteritinib is a commonly used targeted drug for acute myeloid leukemia (AML), but the emergence of gilteritinib resistance greatly reduces the therapeutic effect. RING finger protein 38 (RNF38), a protein with RING Finger domain and E3 ubiquitin ligase activity, has been implicated in tumorigenesis and drug resistance. However, the role and mechanism of RNF38 in the gilteritinib resistance of AML remains unclear.

Methods: Normal AML cells were treated with gilteritinib to construct gilteritinib-resistant cells (MV4-11/Gilteritinib and MOLM-13/Gilteritinib). CCK8 assay, TUNEL staining and EdU assay were used to assess gilteritinib resistance, cell apoptosis and proliferation. The protein levels of autophagy-related markers, RNF38 and LIM homeobox transcription factor 1 alpha (LMX1A) were determined by western blot. Also, RNF38 and LMX1A mRNA levels were tested using qRT-PCR. Autophagic flux was assessed using mRFP-GFP-LC3 labeling, and autophagosome numbers was counted under transmission electron microscopy. Co-IP assay was employed to analyze interaction between RNF38 and LMX1A. The effects of LMX1A and RNF38 on AML tumorigenesis were analyzed by in vivo experiments.

Results: In gilteritinib-resistant AML cells, autophagy-related markers, mRFP-GFP-LC3 signals and autophagosome numbers were significantly enhanced. Autophagy inhibitor 3-MA could suppress gilteritinib resistance in AML cells. RNF38 knockdown inhibited gilteritinib resistance and autophagy in AML cells. Mechanistically, RNF38 reduced LMX1A expression by inducing its ubiquitination. RNF38 overexpression reversed the inhibitory effect of LMX1A on gilteritinib resistance and autophagy in AML cells, as well as AML tumor growth in vivo, while these effects could be abolished by proteasome inhibitor MG132.

Conclusions: RNF38 induced autophagy to promote gilteritinib resistance in AML by increasing the ubiquitination of LMX1A.

RNF38通过调节LMX1A的泛素化来诱导自噬,从而促进急性髓性白血病患者对吉特替尼的耐药性。
研究背景吉特替尼是治疗急性髓性白血病(AML)的常用靶向药物,但吉特替尼耐药性的出现大大降低了治疗效果。RING Finger蛋白38(RNF38)是一种具有RING Finger结构域和E3泛素连接酶活性的蛋白,已被认为与肿瘤发生和耐药性有关。然而,RNF38在AML吉特替尼耐药中的作用和机制仍不清楚:方法:正常AML细胞经吉利替尼处理后构建吉利替尼耐药细胞(MV4-11/吉利替尼和MOLM-13/吉利替尼)。CCK8检测法、TUNEL染色法和EdU检测法用于评估吉仑替尼耐药性、细胞凋亡和增殖。自噬相关标记物 RNF38 和 LIM homeobox 转录因子 1 alpha(LMX1A)的蛋白水平通过 Western 印迹进行了测定。此外,还使用 qRT-PCR 检测了 RNF38 和 LMX1A 的 mRNA 水平。利用mRFP-GFP-LC3标记评估自噬通量,并在透射电子显微镜下计数自噬体数量。Co-IP 分析法用于分析 RNF38 和 LMX1A 之间的相互作用。通过体内实验分析了LMX1A和RNF38对AML肿瘤发生的影响:结果:在吉利替尼耐药的AML细胞中,自噬相关标记物、mRFP-GFP-LC3信号和自噬体数量显著增强。自噬抑制剂3-MA能抑制吉仑替尼耐药的AML细胞。敲除RNF38可抑制吉特替尼耐药和AML细胞的自噬。从机制上讲,RNF38通过诱导LMX1A泛素化来减少其表达。RNF38的过表达逆转了LMX1A对吉利替尼耐药和AML细胞自噬的抑制作用,也逆转了AML肿瘤在体内的生长,而蛋白酶体抑制剂MG132则可消除这些作用:结论:RNF38通过增加LMX1A的泛素化诱导自噬,从而促进吉特替尼对AML的耐药性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cell Biology and Toxicology
Cell Biology and Toxicology 生物-毒理学
CiteScore
9.90
自引率
4.90%
发文量
101
审稿时长
>12 weeks
期刊介绍: Cell Biology and Toxicology (CBT) is an international journal focused on clinical and translational research with an emphasis on molecular and cell biology, genetic and epigenetic heterogeneity, drug discovery and development, and molecular pharmacology and toxicology. CBT has a disease-specific scope prioritizing publications on gene and protein-based regulation, intracellular signaling pathway dysfunction, cell type-specific function, and systems in biomedicine in drug discovery and development. CBT publishes original articles with outstanding, innovative and significant findings, important reviews on recent research advances and issues of high current interest, opinion articles of leading edge science, and rapid communication or reports, on molecular mechanisms and therapies in diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信